肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2012年
11期
735-737,741
,共4页
李晓敏%李琦%武亚娟%任雅琼
李曉敏%李琦%武亞娟%任雅瓊
리효민%리기%무아연%임아경
癌,小细胞肺%胃泌素释放肽前体%神经元特异性烯醇化酶%疗效
癌,小細胞肺%胃泌素釋放肽前體%神經元特異性烯醇化酶%療效
암,소세포폐%위비소석방태전체%신경원특이성희순화매%료효
Carcinoma,small cell lung% Pro-gastrin-releasing peptide% Neuro-specific enolase%Curative effect
目的 探讨不同治疗手段的局限期小细胞肺癌(SCLC)患者分别进行治疗前后血清胃泌素释放肽前体(ProGRP)和神经元特异性烯醇化酶(NSE)水平变化,并评价治疗效果与标志物血清水平的相关性.方法 将150例局限期SCLC患者随机分为3个治疗组,即同步放化疗组、序贯放化疗组、单纯化疗组；应用酶联免疫吸附试验(ELISA)、电化学发光法对3组患者治疗前后ProGRP和NSE水平进行联合检测,并进行数据整理和分析.随访期为1年.结果 3组患者ProGRP及NSE在治疗结束后均明显下降；其ProGRP与NSE的下降幅度依次为同步放化疗组、序贯放化疗组、单纯化疗组(318.96、250.77、226.18 pg/ml及31.72、23.95、17.89 μg/L)；三组按近期疗效好排序,依次为同步放化疗组、序贯放化疗组、单纯化疗组；同步放化疗组明显优于单纯化疗组,差异有统计学意义(P＜0.05).在各组中,治疗有效的患者ProGRP与NSE的下降幅度明显大于治疗无效的患者；病情进展时,相应ProGRP与NSE上升,差异有统计学意义(P＜0.05).结论 ProGRP和NSE水平可反映出局限期SCLC患者的病情变化并可评估疗效；同步放化疗优于序贯放化疗和单纯化疗.
目的 探討不同治療手段的跼限期小細胞肺癌(SCLC)患者分彆進行治療前後血清胃泌素釋放肽前體(ProGRP)和神經元特異性烯醇化酶(NSE)水平變化,併評價治療效果與標誌物血清水平的相關性.方法 將150例跼限期SCLC患者隨機分為3箇治療組,即同步放化療組、序貫放化療組、單純化療組；應用酶聯免疫吸附試驗(ELISA)、電化學髮光法對3組患者治療前後ProGRP和NSE水平進行聯閤檢測,併進行數據整理和分析.隨訪期為1年.結果 3組患者ProGRP及NSE在治療結束後均明顯下降；其ProGRP與NSE的下降幅度依次為同步放化療組、序貫放化療組、單純化療組(318.96、250.77、226.18 pg/ml及31.72、23.95、17.89 μg/L)；三組按近期療效好排序,依次為同步放化療組、序貫放化療組、單純化療組；同步放化療組明顯優于單純化療組,差異有統計學意義(P＜0.05).在各組中,治療有效的患者ProGRP與NSE的下降幅度明顯大于治療無效的患者；病情進展時,相應ProGRP與NSE上升,差異有統計學意義(P＜0.05).結論 ProGRP和NSE水平可反映齣跼限期SCLC患者的病情變化併可評估療效；同步放化療優于序貫放化療和單純化療.
목적 탐토불동치료수단적국한기소세포폐암(SCLC)환자분별진행치료전후혈청위비소석방태전체(ProGRP)화신경원특이성희순화매(NSE)수평변화,병평개치료효과여표지물혈청수평적상관성.방법 장150례국한기SCLC환자수궤분위3개치료조,즉동보방화료조、서관방화료조、단순화료조；응용매련면역흡부시험(ELISA)、전화학발광법대3조환자치료전후ProGRP화NSE수평진행연합검측,병진행수거정리화분석.수방기위1년.결과 3조환자ProGRP급NSE재치료결속후균명현하강；기ProGRP여NSE적하강폭도의차위동보방화료조、서관방화료조、단순화료조(318.96、250.77、226.18 pg/ml급31.72、23.95、17.89 μg/L)；삼조안근기료효호배서,의차위동보방화료조、서관방화료조、단순화료조；동보방화료조명현우우단순화료조,차이유통계학의의(P＜0.05).재각조중,치료유효적환자ProGRP여NSE적하강폭도명현대우치료무효적환자；병정진전시,상응ProGRP여NSE상승,차이유통계학의의(P＜0.05).결론 ProGRP화NSE수평가반영출국한기SCLC환자적병정변화병가평고료효；동보방화료우우서관방화료화단순화료.
Objective To study the correlation of the serum levels of pro-gastrin-releasing peptide (ProGRP) and neuro-specific enolase (NSE) with different treatments in limited-disease small cell lung cancer (L-SCLC) patients.Methods 150 L-SCLC patients were randomly divided into three groups including concurrent chemo-radiotherapy group,sequential chemo-radiotherapy group,and chemotherapy group.The serum levels of ProGRP and NSE were detected by enzyme-linked immunosorbent assay (ELISA) and electrochemiluminescence immunoassay before and after different treatments.The follow-up phase was 12 months.Results The serum levels of ProGRP and NSE were significantly decreased in all 3 groups after treatment (318.96,250.77,226.18 pg/ml and 31.72,23.95,17.89 μg/L),and the lowest level was observed in concurrent chemo-radiotherapy group,then the sequential chemo-radiotherapy group and chemotherapy group.The short term therapeutic effects were in the same sequence,and there was statistical significance between concurrent chemoradiotherapy group and chemotherapy (P ＜ 0.05).The decrease extent of ProGRP and NSE in effective cases (CR+PR) was significantly higher than that in failure cases in all 3 groups.The serum levels of ProGRP and NSE were increased with disease progress (P ＜ 0.05).Conclusion The serum levels of ProGRP and NSE can be used to reflect the patient' s condition and evaluate therapeutic effect in L-SCLC.The concurrent chemo-radiotherapy is more effective than sequential chemo-radiotherapy and chemotherapy only in L-SCLC.
